HTGF backs MYR GmbH
High-Tech Gründerfonds has invested €500,000 in German biotech firm MYR GmbH.
The fresh capital will enable the company to start phase 1 of its clinical development in summer 2011, having successfully completed pre-clinical studies.
Company
Founded in 2010, MYR GmbH is located in Burgwedel near Hannover. The company develops the viral entry inhibitor Myrcludex for the treatment of chronic hepatitis B and D infections. MYR currently has two employees, who are focused on the coordination of the network of academic partners and vendors involved in the Myrcludex development.
People
Dr Bernd Goergen, senior investment manager, handled the investment for High-Tech Gründerfonds.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater